Nov 11, 2026
One teen says GLP-1 treatment changed his daily life. California Trim Clinic says families deserve doctor-led obesity care built around health, function and support.
Westlake Village, CA (PRUnderground) November 11th, 2026

For one teenager recently featured on Good Morning America, treating obesity changed much more than a number on a scale.
Adam Renteria told ABC News that obesity had affected his energy, independence and willingness to go out. After beginning doctor-supervised Wegovy at age 15, his family reported major changes over the following two years, including a BMI reduction from 36 to 22.8, greater physical confidence and enough renewed capability for Adam, now 17, to join a cheer team.
California Trim Clinic says stories like Adam's are helping shift the teen GLP-1 conversation away from appearance and toward something more important: health, function, confidence and participation in everyday life.
Families exploring medical weight management for a teenager ages 12-17 can visit TeenHealthRx.com or schedule a free Discovery Call to learn how doctor-led teen obesity care works.
Obesity affects roughly 1 in 5 U.S. children and adolescents. Pediatric obesity is a common chronic disease with potential effects on cardiovascular, metabolic, physical and emotional health.
Wegovy is FDA-approved for adolescents ages 12 and older with obesity. Semaglutide is approved for chronic weight management in pediatric patients ages 12+ with BMI at or above the 95th percentile for age and sex when used alongside reduced-calorie nutrition and increased physical activity.
Medication is part of comprehensive care, not a replacement for it. Pediatric clinical guidance supports obesity pharmacotherapy for appropriately selected adolescents alongside health behavior and lifestyle treatment.
Every teenager requires individual medical review. GLP-1 treatment is not appropriate for every young person, and prescribing decisions should consider medical history, growth, medications, obesity-related conditions, potential side effects and family support.
Yes. Some adolescents ages 12-17 with obesity may qualify for FDA-approved GLP-1 treatment. Wegovy, the brand name for semaglutide, is FDA-approved for chronic weight management in pediatric patients ages 12 and older with obesity. Eligibility and treatment require individualized medical evaluation and ongoing doctor supervision.
Adam's story resonated because it did not begin with vanity.
According to ABC News, obesity had begun interfering with his energy, independence and daily life. His mother also expressed concern about significantly elevated blood pressure, while his treating pediatric endocrinologist described a teenager who was already active and living in a household with healthy food choices but was finding physical activity increasingly difficult.
That context matters because obesity is a chronic disease influenced by genetic, physiological, environmental and behavioral factors. It cannot always be reduced to willpower, food choices or whether a teenager is "trying hard enough."
For California Trim Clinic, that is the part of the story families should hear loudest.
ABC News reported that Adam's BMI decreased from 36 to 22.8 over approximately two years of treatment.
But the number was only part of what changed.
Adam described a major increase in physical confidence and capability. He joined a cheer team, while his mother said feeling more comfortable in his body had made a meaningful difference in his daily life.
Individual results cannot predict what another teenager will experience, and California Trim Clinic does not guarantee a particular amount of weight loss, BMI reduction, confidence improvement or athletic outcome.
Still, Adam's experience illustrates why adolescent obesity treatment can be about much more than becoming smaller.
It can be about helping a young person participate more fully in their own life.
Healthy nutrition, movement, sleep and family support remain central to pediatric obesity care.
What has changed is the understanding that lifestyle intervention does not always have to stand alone.
The American Academy of Pediatrics recommends that clinicians offer adolescents ages 12 and older with obesity pharmacotherapy according to medication indications, risks and benefits as an adjunct to health behavior and lifestyle treatment.
That means an adolescent who is already active, eating reasonably well or living in a health-conscious household does not automatically need another lecture about discipline.
They may need a medical evaluation.
Families who already know they want to discuss treatment directly can book a $99 physician consultation with Dr. Lynda Szczech.
GLP-1 prescribing for pediatric obesity remains far less common than adult use, but utilization is increasing.
That growth is happening alongside broader recognition that adolescents can experience serious obesity-related health consequences years before adulthood.
At the same time, increased awareness does not mean every teenager with excess weight belongs on a GLP-1 medication.
Teen GLP-1 treatment sits in a middle ground that families deserve to understand clearly: it is an established medical option for appropriately selected adolescents, but it is not an automatic prescription for every young person who wants to lose weight.
Wegovy, or semaglutide, received FDA approval for chronic weight management in pediatric patients ages 12 years and older with obesity.
The indication applies to adolescents with BMI at or above the 95th percentile for age and sex and is used alongside reduced-calorie nutrition and increased physical activity.
That distinction matters because online GLP-1 conversations frequently blur adults, teenagers, different medications and different prescribing situations into one enormous category.
For adolescent obesity specifically, medication selection should follow the actual FDA indication, the teenager's individual medical circumstances and a licensed doctor's judgment.
California Trim Clinic's TeenHealthRx pathway is designed specifically around that structured medical conversation for teens ages 12-17.
Dr. Lynda Szczech, MD, helps guide individualized teen medical weight-management care through California Trim Clinic's TeenHealthRx program.
"When obesity is affecting a teenager's health, mobility, confidence or ability to participate in everyday life, families deserve more than another conversation about trying harder. They deserve to understand the evidence-based medical options that may be available."
Dr. Szczech says medication should be understood as one component of a broader care plan.
"A GLP-1 can be an important tool for the right adolescent, but we are still treating a growing young person. Medical history, nutrition, physical activity, side effects, family support and ongoing monitoring all matter."
She also says stories like Adam's can help families recognize that seeking medical treatment for obesity does not mean lifestyle efforts have failed.
"The goal is not to chase a number for its own sake. We want to help a teenager move toward better health and function in a way that is medically responsible, sustainable and supportive."
Quite a lot.
Adam's treating physician told ABC News that experienced prescribing and strong family support are especially important when young people use obesity medication.
Teen obesity treatment happens inside a household.
Food availability, transportation, schedules, medication administration, follow-up appointments, emotional support and attitudes about body weight can all influence a teenager's experience.
That is why doctor-supervised teen obesity care should involve the family rather than treating medical weight management as a prescription handed to a teenager and forgotten.
Families who want to understand how California Trim Clinic approaches that process can visit TeenHealthRx.com.
No.
GLP-1 medications can influence appetite regulation and weight management, but pediatric obesity is a chronic disease and treatment may be long term.
Doctors and researchers are continuing to study the long-term experience of children and adolescents using GLP-1 medications, including what happens when treatment is discontinued.
That uncertainty does not erase the benefits demonstrated in appropriately selected adolescents.
It does mean families should enter treatment understanding that medical obesity care may require continued follow-up, monitoring and long-term planning.
The first question probably should not be, "How fast will my child lose weight?"
Parents should understand why medication is being considered, which FDA-approved medication is being discussed, how eligibility is determined, which potential side effects deserve attention and how growth and progress will be monitored.
They should also ask how nutrition, movement, family support and ongoing follow-up fit into the treatment plan.
And the practical questions matter too: What does the consultation cost? What might medication cost? How often is follow-up needed? What happens if treatment needs to change?
Families who want those questions answered before deciding whether to proceed can schedule a free Discovery Call with California Trim Clinic.
TeenHealthRx is California Trim Clinic's doctor-led medical weight-management pathway for adolescents ages 12-17.
Care can include virtual medical evaluation, individualized treatment planning, ongoing doctor-guided follow-up, family involvement and medication coordination when treatment is medically justified and legally permitted.
Families can begin by learning about the program and discussing current pricing through a complimentary Discovery Call.
Those ready for direct medical evaluation can book a $99 physician consultation with Dr. Lynda.
Booking a consultation does not guarantee medication or a prescription.
Some adolescents ages 12 and older with obesity may qualify for FDA-approved treatment with Wegovy, or semaglutide.
FDA labeling applies to pediatric patients ages 12+ with obesity defined by BMI at or above the 95th percentile for age and sex. Eligibility still requires individualized medical review.
Yes.
Wegovy is FDA-approved for chronic weight management in pediatric patients ages 12 years and older with obesity when used alongside reduced-calorie nutrition and increased physical activity.
No.
Wegovy's pediatric obesity indication does not require diabetes. A teenager can have obesity requiring medical treatment even when glucose or other metabolic measures appear normal.
No.
FDA-approved pediatric Wegovy treatment is intended for adolescents ages 12+ with obesity, not simply any teenager seeking cosmetic weight loss.
Medical history, BMI percentile, contraindications, medications and individual health factors require doctor review.
No.
Medication is used alongside nutrition, physical activity and other health behaviors rather than replacing them.
There is no single answer for every teenager.
Obesity is a chronic disease, and the appropriate duration of treatment depends on the individual patient's response, medical circumstances and ongoing doctor evaluation.
Families can visit TeenHealthRx.com or schedule a free Discovery Call to ask about the program, pricing and next steps.
Families ready for physician evaluation can book the $99 consultation with Dr. Lynda Szczech.
Adam's story is compelling because the ending was not simply a lower BMI.
It was a teenager describing greater physical capability, joining a cheer team and feeling more confident participating in his own life.
No medication can promise that same experience for another teenager.
But stories like his show why families deserve access to the full medical conversation around adolescent obesity, including FDA-approved pharmacotherapy when it is medically indicated.
For families of teens ages 12-17, California Trim Clinic's TeenHealthRx pathway offers a doctor-led way to ask questions, understand available options and determine whether treatment deserves consideration.
Visit TeenHealthRx.com, schedule a free Discovery Call, or book a $99 physician consultation with Dr. Lynda.
California Trim Clinic
3717 E Thousand Oaks Blvd., Ste. 170
Westlake Village, CA 91362
805-892-8077
This press release is for educational and informational purposes only and does not constitute medical advice, diagnosis or treatment.
GLP-1 medications are not appropriate for every adolescent. Eligibility depends on age, BMI criteria, medical history, medication-specific indications, contraindications and individualized doctor review.
Wegovy is FDA-approved for chronic weight management in pediatric patients ages 12 years and older with obesity when used alongside reduced-calorie nutrition and increased physical activity.
Results vary. California Trim Clinic does not guarantee a particular amount of weight loss, BMI reduction, improvement in confidence, athletic performance or another treatment outcome.
Treatment requires individualized evaluation by a licensed doctor and is available only when medically justified and legally permitted.
Original Press Release.
Kookmin University established the QNX Centre Korea on Nov. 4 in partnership with QNX, a global provider of embedded software and operating systems, to provide specialized education in the field. The university said the center will serve as a platform for industry-academia collaboration aimed at nurturing talent in embedded software. Through the partnership, Kookmin University becomes the first university in Korea to introduce a curriculum based on QNX technology. QNX, a division of BlackBerry Limited, provides operating systems and software development technologies for industries where safety and reliability are critical, including the automotive, medical device and industrial automation sectors. The university plans to develop the center into a hub for embedded software education and industry-academia cooperation, connecting academic institutions, government agencies and industry partners across Korea. The initiative aims to cultivate skilled professionals in various fields, including software-defined vehicles, robotics, industrial automation, smart factories and the industrial internet
Sogang University and the Korea Institute of Science and Technology (KIST) have signed a memorandum of understanding to expand joint research and foster specialized talent in semiconductors, clean hydrogen and space-related composite materials. The agreement was signed by Sogang President Sim Jong-hyeok and KIST President Oh Sang-rok at the Sogang’s Seoul campus on Nov. 11, the universities said. The partnership will combine KIST’s mission-oriented research capabilities with Sogang’s academic and educational strengths to advance strategic technologies and nurture the next generation of researchers. “Our partnership with KIST, which has been at the forefront of science and technology development in Korea, will further strengthen Sogang’s research and educational capabilities,” Sim said. He added that the university would support students in taking part in key national research projects and preparing to lead future industries. Oh noted that KIST has shifted its focus from individual research projects to collaborative research aimed at addressing national challenges, while expand
Hankuk University of Foreign Studies (HUFS) has signed a memorandum of understanding with the Korea National University of Arts (K-Arts) to expand their joint academic programs. HUFS said the signing ceremony was held Tuesday at HUFS’ Seoul campus, with its President Kang Kee-hoon and K-Arts President Pyeon Jang-wan in attendance. The agreement aims to broaden the scope of the two universities’ joint general education programs, which have been running for 12 years, and strengthen the foundation for interdisciplinary education by leveraging their respective academic resources. The universities plan to establish a new model of cross-university educational cooperation that transcends institutional boundaries by combining HUFS’ expertise in artificial intelligence (AI) education with K-Arts’ specialization in arts education. “The combination of HUFS’ basic AI education curriculum and K-Arts’ expertise in arts education will provide students with an opportunity to develop new interdisciplinary competencies beyond university boundaries,” Kang said. “Bringing together the arts,
Education Minister Choi Kyo-jin offered to resign Sunday, taking responsibility for confusion over anti-cheating measures in the run-up to the 2027 College Scholastic Ability Test (CSAT). President Lee Jae Myung accepted his resignation within an hour. "Last-minute changes in preparations for the CSAT caused inconvenience to the public, particularly test takers," Choi said in a statement released by the ministry. With the exam now over, Choi acknowledged responsibility for the confusion and announced his decision to step down. The resignation followed mounting criticism of the ministry's slow response to concerns over artificial intelligence (AI)-assisted cheating ahead of the CSAT, Korea's high-stakes college entrance exam. The government repeatedly revised its anti-cheating measures just days before the test, leaving students and test administrators scrambling to keep up with the changes. The ministry initially focused its anti-cheating measures on smart glasses but expanded them to cover other high-tech devices after the top scorer on the tax accountant exam admitted on Nov. 15 to using
Raywatt, a medical device startup founded by a Sejong University professor, has raised 13 billion won ($9.7 million) in a new funding round, bringing its cumulative funding to more than 23.5 billion won. Ha Jin-yong, a professor in the university’s Department of AI Convergence Electronics Engineering, launched the company in 2019. It specializes in medical imaging devices for cardiovascular and cerebrovascular diagnosis. The investors included participation from InterVest, Life Asset Management, Ryukyung PSG Asset Management, Hyundai Venture Investment, L&S Venture Capital, Eugene Investment & Securities and EcoPro Partners. Investors recognized Raywatt’s achievements in commercializing its technology both in Korea and overseas. The company’s technology has been used in more than 100 clinical cases at Severance Cardiovascular Hospital in Seoul. It has also been designated an innovative prototype product by the Public Procurement Service. Raywatt obtained marketing approval in Vietnam and won a tender for government hospitals in the United Arab Emirates. Its flagship product, FASTER O
The Ministry of Agriculture, Food and Rural Affairs said Sunday that it held its first-ever Kimchi Global Vision Declaration ceremony in New York on Friday (local time) to mark the seventh annual Kimchi Day and promote kimchi in global markets. Kimchi Day was first designated on Nov. 22, 2020 to honor kimchi's cultural heritage, ingredients and health benefits. The event, held at the Korean Cultural Center New York, brought together about 100 participants, including New York State Assemblymember Ron Kim, Korean Consul General in New York Kim Sang-ho, chef Hooni Kim and local food industry representatives. During the event, Jeong Gyeong-seok, director general of the ministry's Food Industry Policy Bureau, outlined four priorities: studying kimchi's potential benefits for gut health and immunity; using artificial intelligence to automate production and improve quality control; preserving more than 200 regional and seasonal varieties while expanding education; and working with retailers and restaurants to expand offerings, including vegan kimchi. As part of the ceremony, participants placed
The Coast Guard said Sunday it confirmed that an object found on the seabed off Korea's west coast was the hull of the missing fishing boat Haegwangho, as the search entered its fifth day. The Coast Guard had been working to identify the object it had earlier discovered lying on the seabed near where the Haegwangho went missing off the western coastal county of Taean last Wednesday. Coast Guard officials confirmed that what had appeared to be a sunken ship was the missing boat. The Haegwangho, a 7.93-ton boat carrying three Koreans and four Indonesians, was reported missing early last Wednesday. It had left a port in Taean two days earlier.
Sungkyunkwan University hosted the 14th Sungkyun International Solar Forum at its Seoul campus from Nov. 11-13, bringing together researchers to discuss advances in perovskite solar cells and optoelectronic devices. The forum came amid growing demand for carbon-free energy sources to address the climate crisis, as electricity demand continues to rise due to the expansion of artificial intelligence (AI) data centers and the increasing adoption of electric vehicles. Commercializing perovskite solar cells, which are seen as a next-generation power generation technology, and developing technologies for mass production have emerged as key challenges. Park Nam-gyu, a distinguished professor of chemical engineering at the university and director of the SKKU National Laboratory for Intelligent Energy Solution Technology, chaired the forum’s organizing committee. He presented the latest research findings on perovskite solar cells and outlined technological developments aimed at their commercialization. The university said Park was the first researcher in the world to develop solid-state perovski
The ruling Democratic Party of Korea (DPK) laid out its grounds Sunday for impeaching Supreme Court Chief Justice Cho Hee-dae and said it would seek a National Assembly vote by the end of December, drawing criticism that the move could undermine judicial independence. At its first public briefing at the Assembly, the party’s impeachment task force pointed to the Supreme Court’s handling of President Lee Jae Myung’s election law case and Cho’s refusal to recommend a new candidate for a vacant Supreme Court seat. “We will do our utmost to finalize the impeachment motion as quickly as possible and bring it to a vote in the National Assembly before the end of December,” said Rep. Yang Bu-nam, who leads the task force. He did not give a date for filing the motion. Other grounds previously raised by the party include the court’s response to the Dec. 3, 2024, martial law declaration, allegations over court operating expenses and cash payments, and Cho’s refusal to testify before the Assembly. The DPK made pursuing Cho’s impeachment its official position Friday, a day after the
The Korea National Railway and two Korean engineering firms will take part in a project to develop a high-speed railway connecting northern and southern Vietnam, spanning 1,541 kilometers between Hanoi and Ho Chi Minh City, according to Korea's Ministry of Land, Infrastructure and Transport, Sunday. A consortium comprising Korean, French and Vietnamese companies has won a contract for a feasibility study and front-end engineering design (FEED) for the project. The contract was tendered by the Thang Long Project Management Unit under Vietnam's Ministry of Construction. The consortium includes state-run Korea National Railway and Korean engineering firms Yooshin and Sambo, along with France's Systra and Vietnam's Tedi, both of which specialize in railway design. The consortium won the contract in competition with 40 other bidders, according to the ministry. The initial phase of the project is valued at 560 billion won ($416 million), with the consortium set to carry out the work over 30 months. The study and design work will cover four sections: a 281-kilometer stretch between Hanoi and Vin
Samsung Electronics and SK hynix could face a sharp memory price decline if hyperscalers scale back the artificial intelligence (AI) spending that has driven the current chip boom, according to a renowned U.S. semiconductor analyst. Jim Handy, founder and general director at Objective Analysis, said in an interview with The Korea Times that the surge in memory prices — caused by a sharp increase in demand — is “temporary,” echoing concerns among some Korean analysts that the current memory cycle may be nearing its peak. “I do not think that AI demand is growing that quickly, so they are likely to slow their spending at some point, and that will cause memory prices to collapse,” Handy said. Although the timing of a downturn is difficult to predict, memory prices could eventually fall back to 2024 levels once demand weakens, he said. Handy has raised particular concerns over the scale of spending by hyperscalers such as Google, Meta, Amazon and OpenAI. These companies are spending roughly 40 percent of their revenue on capital expenditures, including massive investments in AI c
The Korean Railway Workers' Union said Sunday it has postponed its planned work-to-rule action to later this week to prioritize the restoration of train services following a recent freight train derailment. The union had planned to launch the work-to-rule action at 9 a.m. Monday, with workers strictly following work rules to demand more maintenance and station staff, and expanded facilities for high-speed train maintenance and storage. But it decided to postpone the labor action by three days to Thursday, after a freight train derailed at Sojeong-ri Station on the Gyeongbu Line in Sejong on Saturday morning, disrupting train services in the area. "We will postpone the work-to-rule action until rail services are stabilized and do our best to support the recovery effort," the union said, adding it would call for measures to prevent a recurrence once the cause of the accident is identified. No casualties were reported, but power outages and track obstructions disrupted services, leading to the suspension of regular passenger trains on the line Saturday. Train services had returned to normal
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.